This includes options like intrauterine devices (IUDs), injections, implants, rings, and patches
This poses another limitation, casting doubt on the generalizability of our findings
5 These guidelines align with the American Diabetes Association (ADA) standards of care which also provide strong recommendations based on robust clinical trial data supporting the cardiovascular benefits of GLP-1 RAs, particularly in patients with established cardiovascular disease and chronic kidney disease (CKD)
It includes GLP-1 receptor activity, but unlike semaglutide, it is a triple agonist, also targeting GIP and glucagon receptors for broader metabolic effects
- Reduction of insulin secretion (calcium antagonists, diazoxide, somatostatin analogues, IL-1 receptor antagonist)